JAK Inhibitors for Myelofibrosis: Strengths and Limitations.
- Published in:
- Current Hematologic Malignancy Reports, 2024, v. 19, n. 6, p. 264, doi. 10.1007/s11899-024-00744-9
- By:
- Publication type:
- Article
Works matching IS 15588211 AND DT 2024 AND VI 19 AND IP 6
Results: 7
1
2
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas.
- Published in:
- Current Hematologic Malignancy Reports, 2024, v. 19, n. 6, p. 276, doi. 10.1007/s11899-024-00743-w
- By:
- Publication type:
- Article
3
Advances in Stem Cell Transplantation for Myelofibrosis.
- Published in:
- Current Hematologic Malignancy Reports, 2024, v. 19, n. 6, p. 256, doi. 10.1007/s11899-024-00742-x
- By:
- Publication type:
- Article
4
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease.
- Published in:
- Current Hematologic Malignancy Reports, 2024, v. 19, n. 6, p. 246, doi. 10.1007/s11899-024-00741-y
- By:
- Publication type:
- Article
5
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.
- Published in:
- Current Hematologic Malignancy Reports, 2024, v. 19, n. 6, p. 237, doi. 10.1007/s11899-024-00740-z
- By:
- Publication type:
- Article
6
Pulmonary, Hepatic, and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Telomere Biology Disorders.
- Published in:
- Current Hematologic Malignancy Reports, 2024, v. 19, n. 6, p. 293, doi. 10.1007/s11899-024-00724-z
- By:
- Publication type:
- Article
7
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders.
- Published in:
- Current Hematologic Malignancy Reports, 2024, v. 19, n. 6, p. 285, doi. 10.1007/s11899-023-00720-9
- By:
- Publication type:
- Article